<SEC-DOCUMENT>0001157523-20-000361.txt : 20200317
<SEC-HEADER>0001157523-20-000361.hdr.sgml : 20200317
<ACCEPTANCE-DATETIME>20200317170515
ACCESSION NUMBER:		0001157523-20-000361
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20200317
FILED AS OF DATE:		20200317
DATE AS OF CHANGE:		20200317

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aurinia Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001600620
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36421
		FILM NUMBER:		20721861

	BUSINESS ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
		BUSINESS PHONE:		250-708-4272

	MAIL ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a52190033.htm
<DESCRIPTION>AURINIA PHARMACEUTICALS INC. 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 6.5.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div><br>
  </div>
  <div>
    <div><br>
    </div>
    <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">Washington, D.C. 20549</div>
    <div>&#160;</div>
    <div>&#160;
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">FORM 6-K</div>
    <div>&#160;
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div>&#160;</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER<br>
      PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE<br>
      SECURITIES EXCHANGE ACT OF 1934</div>
    <div>&#160;</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">Dated March 17, 2020</div>
    <div>&#160;</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">Commission File Number 001-36421</div>
    <div>&#160;</div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">AURINIA PHARMACEUTICALS INC.</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">(Exact name of Registrant as specified in its charter)</div>
    <div>&#160;</div>
    <div>&#160;
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="text-align: center; color: #000000; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; color: #000000; font-weight: bold;">N/A</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">(Translation of Registrant&#8217;s Name)</div>
    <div>&#160;</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">#1203-4464 Markham Street<br>
      Victoria, British Columbia<br>
      V8Z7X8<br>
      (250) 708-4272<br>
      (Address and telephone number of registrant&#8217;s principal executive offices)</div>
    <div>&#160;
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div>&#160;</div>
    <div style="margin-left: 21.6pt; color: #000000;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
    <div>&#160;</div>
    <div style="text-align: center; color: #000000;">Form 20-F &#9744;&#160;&#160;&#160; Form 40-F &#9746;</div>
    <div>&#160;</div>
    <div style="margin-left: 21.6pt; color: #000000;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</div>
    <div>&#160;</div>
    <div style="margin-left: 21.6pt; color: #000000;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 21.6pt; color: #000000;">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule
      12g3-2(b) under the Securities Exchange Act of 1934.</div>
    <div>&#160;</div>
    <div style="text-align: center; color: #000000;">Yes &#9746;&#160;&#160; No &#9744;</div>
    <div>&#160;</div>
    <div style="text-indent: 21.6pt; margin-right: 14.4pt; color: #000000;">This Form 6-K is hereby filed and incorporated by reference in the registrant&#8217;s Registration Statement on Form F-10 (File No. 333-222413).</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div>&#160;</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">SIGNATURES</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 21.6pt; margin-right: 3.6pt; color: #000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
      thereunto duly authorized.</div>
    <div>&#160;</div>
    <div style="color: #000000;">Dated: March 17, 2020</div>
    <div>&#160;</div>
    <div> <br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" id="zb8841c73069c491999f7a626dabe11ac" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td colspan="2" rowspan="1" style="font-weight: bold;">Aurinia Pharmaceuticals Inc.</td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%;">
              <div>&#160;</div>
            </td>
            <td style="width: 47%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%; padding-bottom: 2px;">By:<br>
            </td>
            <td style="width: 47%; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Peter S. Greenleaf</td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%;">
              <div>&#160;</div>
            </td>
            <td style="width: 47%;"> Name: Peter S. Greenleaf</td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%;">
              <div>&#160;</div>
            </td>
            <td style="width: 47%;">Title: Chief Executive Officer</td>
          </tr>

      </table>
    </div>
    <div> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="margin-left: 313.2pt; color: #000000;"></div>
    <div><br>
    </div>
    <div style="text-align: center; color: #000000; font-weight: bold;">EXHIBIT INDEX</div>
    <div>&#160;</div>
    <div><br>
      <font style="font-weight: bold; color: #000000;"></font></div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="zd61e1377336f4fbf8cd2f2bd62054978">

          <tr>
            <td style="width: 7%; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; color: #000000;">Exhibit</font></td>
            <td style="width: 3%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
            <td style="width: 90%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div><font style="font-weight: bold; color: #000000;">Description of Exhibit</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 7%;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%;">
              <div>&#160;</div>
            </td>
            <td style="width: 90%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 7%;"><a href="a52190033ex99_1.htm">99.1</a><br>
            </td>
            <td style="width: 3%;">
              <div>&#160;</div>
            </td>
            <td style="width: 90%;"><a href="a52190033ex99_1.htm">News Release - Aurinia Pharmaceuticals Establishes U.S Commercial Operations Center in
                Rockville, Maryland.</a></td>
          </tr>

      </table>
    </div>
    <div>
      <div> </div>
    </div>
    <div>&#160;</div>
    <div style="margin-right: 14.4pt; color: #000000;">Exhibit 99.1 included with this report on Form 6-K is hereby incorporated by reference as exhibits to the Registration Statement on Form F-10 of Aurinia Pharmaceuticals Inc. (File No. 333-222413), as
      amended or supplemented.</div>
    <div>&#160;</div>
    <div> <br>
    </div>
    <div style="text-align: center; color: #000000;">3</div>
    <div><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a52190033ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 6.5.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div> <br>
  </div>
  <div>
    <div class="bw-release">
      <h1 style="text-align: center; list-style-position:inside;FONT-SIZE: 14pt;"> <b>Aurinia Pharmaceuticals Establishes U.S. Commercial Operations Center in Rockville, Maryland</b> </h1>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p style="list-style-position: inside; font-weight: normal;">VICTORIA, British Columbia--(BUSINESS WIRE)--March 17, 2020--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (&#8220;Aurinia&#8221; or the &#8220;Company&#8221;), a late-stage clinical biopharmaceutical
            company focused on advancing voclosporin in multiple indications, today announced that the Company has established its U.S. commercial center of operations in Rockville, Maryland. The new site will support Aurinia&#8217;s plans for growth as it
            prepares for the potential approval and launch of voclosporin for the treatment of lupus nephritis in 2021. </p>
          <p> &#8220;We are thrilled to announce the opening of our U.S. commercial offices in Montgomery County, Maryland, as we continue to advance the development of voclosporin, which has the potential to become the first-ever approved treatment for patients
            suffering from lupus nephritis. This important milestone follows the recent build-out of our commercial leadership team, as we move swiftly, yet responsibly, toward commercial readiness,&#8221; said Peter Greenleaf, President and Chief Executive
            Officer of Aurinia. &#8220;Maryland&#8217;s commitment to attracting and supporting leading innovators played a key role in our decision to establish Aurinia&#8217;s U.S. presence here. We look forward to joining and contributing to the ecosystem of top-notch
            biopharmaceutical companies and research institutions in Montgomery County, while we work to build a global company.&#8221; </p>
          <p> Aurinia&#8217;s Rockville site at 77 Upper Rock Circle will initially occupy 30,000 square feet, with potential expansions to 120,000 square feet. The company plans to hire up to 100 employees in the first year and up to 500 employees as the
            company expands its operations. It is located within the I-270 life sciences and biotech corridor, which is widely recognized as a hotbed of leading innovation and industry talent. </p>
          <p> The Maryland Department of Commerce has approved a $2 million conditional loan through Advantage Maryland, formerly the Maryland Economic Development Assistance Authority and Fund (MEDAAF), which will be distributed in $1 million increments
            as each phase of the project is complete. Additionally, Montgomery County has approved a conditional grant of $350,000 per phase of the project, with the City of Rockville contributing $25,000 for each phase. The company is also eligible for
            Maryland&#8217;s Job Creation Tax Credit. </p>
          <p> Aurinia also announced on February 25, 2020, the appointment of Max Colao, to the newly created role of Chief Commercial Officer, along with the addition of a team of experts across key commercial functions in preparation for the potential
            commercial launch of voclosporin in early 2021. </p>
          <p> <b>About Aurinia</b> </p>
          <p style="list-style-position: inside; font-weight: normal;"> Aurinia Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted
            by diseases with a high unmet medical need. The Company is currently developing an investigational drug for the treatment of lupus nephritis, focal segmental glomerulosclerosis and dry eye syndrome. The Company&#8217;s head office is in Victoria,
            British Columbia and focuses its development efforts globally. For further information, see our website at www.auriniapharma.com. </p>
          <div> </div>
          <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
            <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> <b>Forward-Looking Statements</b> </p>
          <p> Certain statements made in this press release may constitute forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable United States securities law.
            These forward-looking statements or information include but are not limited to statements or information with respect to: completing NDA priority review submissions in a successful and timely manner including the anticipated NDA filing during
            the second quarter of 2020; the potential for commercial launch of voclosporin for use in LN in the first half of 2021; voclosporin having the potential to become the first-ever approved treatment for patients suffering from lupus nephritis;
            voclosporin being potentially a best-in-class CNI with robust intellectual property exclusivity; ; that Aurinia has hired seasoned, distinguished world- class commercial leadership; that voclosporin may be positioned to become the standard of
            care for people living with LN. It is possible that such results or conclusions may change based on further analyses of these data. Words such as &#8220;anticipate&#8221;, &#8220;will&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;target&#8221;, &#8220;plan&#8221;, &#8220;goals&#8221;,
            &#8220;objectives&#8221;, &#8220;may&#8221; and other similar words and expressions, identify forward-looking statements. We have made numerous assumptions about the forward-looking statements and information contained herein, including among other things, assumptions
            about: the market value for the LN, DES and FSGS programs; that another company will not create a substantial competitive product for Aurinia&#8217;s LN, DES and FSGS business without violating Aurinia&#8217;s intellectual property rights; the burn rate of
            Aurinia&#8217;s cash for operations; the costs and expenses associated with Aurinia&#8217;s clinical trials; the planned studies achieving positive results; Aurinia being able to extend and protect its patents on terms acceptable to Aurinia; and the size
            of the LN, DES or FSGS markets; Aurinia will be able to obtain all necessary regulatory approvals for commercialization of voclosporin for use in LN on terms that are acceptable to it and that are commercially viable; and that Aurinia&#8217;s
            intellectual property rights are valid and do not infringe the intellectual property rights of other parties. Even though the management of Aurinia believes that the assumptions made, and the expectations represented by such statements or
            information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate. </p>
          <p> Forward-looking information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aurinia to be materially different
            from any future results, performance or achievements expressed or implied by such forward-looking information. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may
            vary materially from those described in forward-looking statements or information. Such risks, uncertainties and other factors include, among others, the following: difficulties, delays, or failures we may experience in the conduct of our
            clinical trial; difficulties we may experience in completing the development and commercialization of voclosporin; the market for the LN, DES and FSGS business may not be as estimated; Aurinia may have to pay unanticipated expenses; estimated
            costs for clinical trials may be underestimated, resulting in Aurinia having to make additional expenditures to achieve its current goals; Aurinia not being able to extend or fully protect its patent portfolio for voclosporin; competitors may
            arise with similar products; Aurinia may not be able to obtain necessary regulatory approvals for commercialization of voclosporin in a timely fashion, or at all; and Aurinia may not be able to obtain sufficient supply to meet commercial demand
            for voclosporin in a timely fashion. Although we have attempted to identify factors that would cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other
            factors that cause actual results, performances, achievements or events to not be as anticipated, estimated or intended. Also, many of the factors are beyond our control. There can be no assurance that forward-looking statements or information
            will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, you should not place undue reliance on forward-looking statements or information. </p>
          <p> Except as required by law, Aurinia will not update forward-looking information. All forward-looking information contained in this press release is qualified by this cautionary statement. Additional information related to Aurinia, including a
            detailed list of the risks and uncertainties affecting Aurinia and its business can be found in Aurinia&#8217;s most recent Annual Information Form available by accessing the Canadian Securities Administrators&#8217; System for Electronic Document Analysis
            and Retrieval (SEDAR) website at www.sedar.com or the U.S. Securities and Exchange Commission&#8217;s Electronic Document Gathering and Retrieval System (EDGAR) website at www.sec.gov/edgar. </p>
          <p> <i>We seek safe harbour.</i> </p>
        </div>
        <div class="bw-release-contact">
          <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
          <p> <b>Investor &amp; Corporate Contact: <br>
            </b>Glenn Schulman, PharmD <br>
            MPH Corporate Communications, Aurinia <br>
            gschulman@auriniapharma.com </p>
          <p> <b>Media Contact </b><br>
            Krystle Gibbs <br>
            Ten Bridge Communications <br>
            krystle@tenbridgecommunications.com </p>
        </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
